UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
or
|
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-40925
Xilio Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
Delaware |
85-1623397 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
|
|
828 Winter Street, Suite 300 Waltham, Massachusetts |
02451 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: (857) 524-2466
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
Common stock, par value $0.0001 per share |
|
XLO |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
|
|
|
|
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
|
|
|
|
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Number of shares of the registrant's common stock, $0.0001 par value per share, outstanding on November 6, 2026: 7,063,982
References to Xilio
Unless otherwise stated, all references to “us,” “our,” “we,” “Xilio,” “Xilio Therapeutics,” “the Company” and similar references in this Quarterly Report on Form 10-Q refer to Xilio Therapeutics, Inc. and its consolidated subsidiaries. Xilio Therapeutics and its associated logos are registered trademarks of Xilio Therapeutics, Inc. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” or the negative of these words or other comparable terminology, although not all forward-looking statements contain these identifying words.
The forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
•the initiation, timing, progress and results of our research and development programs, including preclinical studies and clinical trials;
•our estimates regarding expenses, future revenue and capital requirements and our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash and cash equivalents;
•our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including our collaboration agreement with AbbVie Group Holdings Limited, or AbbVie, and our license agreement with Gilead Sciences, Inc., or Gilead;
•our expectations regarding milestones, option-related fees and other contingent payments under our collaboration agreement with AbbVie and our license agreement with Gilead;
•the potential receipt of up to $36.2 million in additional gross proceeds in the fourth quarter of 2026 if all outstanding Series C common stock warrants issued in connection with our June 2025 follow-on offering are exercised at their current exercise price of $10.50 per warrant;
•our ability to secure additional capital in the future;
•the potential advantages and benefits of our current and future product candidates, including our beliefs regarding the potential benefits of our current and future product candidates in combination with other agents;
•our strategic plans to research, develop and, if approved, subsequently commercialize any product candidates we may develop;
•our ability to identify additional products, product candidates or technologies with significant potential that are consistent with our research, development and commercial objectives;
•our manufacturing capabilities and strategy, including our reliance on third parties to manufacture our current or future product candidates;
•our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;
•the timing of and our ability to submit investigational new drug applications or biologic license applications for, and, if cleared or approved, maintain such regulatory applications or approvals for our product candidates;
•our commercialization and marketing capabilities and strategy related to our product candidates, if approved;
•the rate and degree of market acceptance of our product candidates, if approved;
•our estimates regarding the addressable patient population and potential market opportunity for our current and future product candidates;
•developments relating to or impacting our competitors and our industry;
•the impact of current or future government laws and regulations on us or third parties with whom we do business and our industry;
•our competitive position and expectations regarding developments and projections relating to our current or future competitors and any competing therapies that are or become available;
•our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act, or JOBS Act; and
•the impact of general economic conditions, including inflation and the imposition of new or revised global trade tariffs.
Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly those described in the “Risk Factor Summary” and “Risk Factors” section in Part II, Item 1A of this Quarterly Report on Form 10-Q, that could cause actual results or events to differ materially from the forward-looking statements that we make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make or enter into.
You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results, performance or achievements may be materially different from what we expect. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
Risk Factor Summary
Our business is subject to numerous risks that, if realized, could materially and adversely affect our business, financial condition, results of operations and future growth prospects. These risks are discussed more fully in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. These risks include, but are not limited to, the following:
•We will need to obtain substantial additional capital in the future to finance our operations and complete the development of any current or future product candidates.
•We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future.
•Our business is highly dependent on the success of our current product candidates, which are in the early stages of development and will require significant additional preclinical and clinical development before we can seek regulatory approval for and commercially launch a product.
•Our approach to the discovery and development of product candidates based on our technological approaches is unproven, and we do not know whether we will be able to develop any products of commercial value.
•Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.
•We may encounter substantial delays in the commencement or completion, or termination or suspension, of our clinical trials, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
•Our product candidates may cause undesirable or unexpectedly severe side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
•Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
•We expect to develop certain of our product candidates in combination with third-party drugs and we will have limited or no control over the safety, supply, regulatory status or regulatory approval of such third-party drugs.
•Manufacturing biologics is complex, and we may experience manufacturing problems that result in delays in our development or commercialization programs.
•Certain of our research and development and manufacturing activities take place in China through WuXi Biologics (Hong Kong) Limited, or WuXi Biologics. A significant disruption in our ability to rely on WuXi Biologics could materially adversely affect our business, financial condition and results of operations.
•We expect to rely on third parties to conduct, supervise and monitor investigational new drug application enabling studies and clinical trials, and to perform other functions for us, and if these third parties perform in an unsatisfactory manner, it may harm our business, reputation and results of operations.
•We have entered into, and may in the future seek to enter into, licenses, collaborations or similar arrangements with third parties for the research, development and commercialization of certain of our current or future product candidates. If any such arrangements are not successful, we may not be able to capitalize on the market potential of those product candidates.
•We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
•If we are unable to obtain and maintain patent protection for any product candidates we develop or for other proprietary technologies we may develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates and technology similar or identical to our product candidates and technology, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.
•We rely on in-license agreements for patent rights with respect to our product candidates and may in the future acquire or in-license additional third-party intellectual property rights on which we may similarly rely. We face risks with respect to such reliance, including the risk that we could lose these rights that are important to our business if we fail to comply with our obligations under these licenses or that we may be unable to acquire or in-license third-party intellectual property that may be necessary or important to our business operations.
•Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate.
•Our common stock may be subject to a low trading volume and volatile market price related or unrelated to our operations and purchasers of our common stock could have difficulty selling their shares or could suffer a decline in value.
Availability of Other Information About Xilio Therapeutics, Inc.
Investors and others should note that we communicate with our investors and the public using our company website (www.xiliotx.com), including but not limited to investor presentations and scientific presentations, filings with the U.S. Securities and Exchange Commission, press releases, public conference calls and webcasts. You can also connect with us on LinkedIn. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media and others interested in our company to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website (ir.xiliotx.com) and may include other social media channels than the ones described above. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
XILIO THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2026 |
|
|
2025 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
|
122,182 |
|
|
$ |
|
137,531 |
|
Collaboration and license agreement receivable |
|
|
|
— |
|
|
|
|
5,000 |
|
Prepaid expenses and other current assets |
|
|
|
4,316 |
|
|
|
|
2,496 |
|
Total current assets |
|
|
|
126,498 |
|
|
|
|
145,027 |
|
Restricted cash |
|
|
|
1,825 |
|
|
|
|
1,807 |
|
Property and equipment, net |
|
|
|
3,086 |
|
|
|
|
3,892 |
|
Operating lease right-of-use asset |
|
|
|
3,423 |
|
|
|
|
3,959 |
|
Total assets |
|
$ |
|
134,832 |
|
|
$ |
|
154,685 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
|
753 |
|
|
$ |
|
3,168 |
|
Accrued expenses |
|
|
|
9,171 |
|
|
|
|
11,739 |
|
Deferred revenue, current portion |
|
|
|
15,407 |
|
|
|
|
40,023 |
|
Operating lease liability, current portion |
|
|
|
1,468 |
|
|
|
|
1,343 |
|
Total current liabilities |
|
|
|
26,799 |
|
|
|
|
56,273 |
|
Deferred revenue, net of current portion |
|
|
|
9,927 |
|
|
|
|
20,635 |
|
Operating lease liability, net of current portion |
|
|
|
4,492 |
|
|
|
|
5,611 |
|
Common stock warrant liabilities |
|
|
|
25,380 |
|
|
|
|
29,560 |
|
Liabilities to issue common stock |
|
|
|
— |
|
|
|
|
7,333 |
|
Total liabilities |
|
|
|
66,598 |
|
|
|
|
119,412 |
|
Commitments and contingencies (Note 7) |
|
|
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
Preferred stock, $0.0001 par value; 5,000,000 shares authorized, no shares issued or outstanding |
|
|
|
— |
|
|
|
|
— |
|
Common stock, $0.0001 par value; 600,000,000 shares authorized; 6,587,811 shares issued and outstanding at September 30, 2026; 4,530,641 shares issued and outstanding at December 31, 2025 |
|
|
|
1 |
|
|
|
|
— |
|
Additional paid-in capital |
|
|
|
508,872 |
|
|
|
|
454,062 |
|
Accumulated deficit |
|
|
|
(440,639 |
) |
|
|
|
(418,789 |
) |
Total stockholders’ equity |
|
|
|
68,234 |
|
|
|
|
35,273 |
|
Total liabilities and stockholders’ equity |
|
$ |
|
134,832 |
|
|
$ |
|
154,685 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
XILIO THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaboration and license revenue |
|
$ |
|
9,984 |
|
|
$ |
|
19,066 |
|
|
$ |
|
41,324 |
|
|
$ |
|
30,080 |
|
Total revenue |
|
|
|
9,984 |
|
|
|
|
19,066 |
|
|
|
|
41,324 |
|
|
|
|
30,080 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
|
14,805 |
|
|
$ |
|
14,321 |
|
|
$ |
|
49,196 |
|
|
$ |
|
37,917 |
|
General and administrative |
|
|
|
6,928 |
|
|
|
|
6,674 |
|
|
|
|
21,480 |
|
|
|
|
22,309 |
|
Total operating expenses |
|
|
|
21,733 |
|
|
|
|
20,995 |
|
|
|
|
70,676 |
|
|
|
|
60,226 |
|
Loss from operations |
|
|
|
(11,749 |
) |
|
|
|
(1,929 |
) |
|
|
|
(29,352 |
) |
|
|
|
(30,146 |
) |
Other income (expense), net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of common stock warrant liabilities |
|
|
|
4,820 |
|
|
|
|
(15,380 |
) |
|
|
|
4,180 |
|
|
|
|
(15,430 |
) |
Other income, net |
|
|
|
981 |
|
|
|
|
1,022 |
|
|
|
|
3,322 |
|
|
|
|
180 |
|
Total other income (expense), net |
|
|
|
5,801 |
|
|
|
|
(14,358 |
) |
|
|
|
7,502 |
|
|
|
|
(15,250 |
) |
Net loss and comprehensive loss |
|
$ |
|
(5,948 |
) |
|
$ |
|
(16,287 |
) |
|
$ |
|
(21,850 |
) |
|
$ |
|
(45,396 |
) |
Net loss per share, basic and diluted |
|
$ |
|
(0.30 |
) |
|
$ |
|
(1.58 |
) |
|
$ |
|
(1.18 |
) |
|
$ |
|
(6.03 |
) |
Weighted average common shares outstanding, basic and diluted |
|
|
|
19,687,818 |
|
|
|
|
10,293,347 |
|
|
|
|
18,492,240 |
|
|
|
|
7,524,228 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
XILIO THERAPEUTICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
For the three months ended September 30, 2026 and 2025
(In thousands, except share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Total |
|
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Stockholders' |
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity |
|
Balance at June 30, 2026 |
|
|
6,580,149 |
|
|
$ |
|
1 |
|
|
$ |
|
506,954 |
|
|
$ |
|
(434,691 |
) |
|
$ |
|
72,264 |
|
Issuance of common stock in connection with the exercise of prefunded warrants |
|
|
7,501 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
Exercise of stock options |
|
|
161 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
Stock-based compensation expense |
|
|
— |
|
|
|
|
— |
|
|
|
|
1,918 |
|
|
|
|
— |
|
|
|
|
1,918 |
|
Net loss |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(5,948 |
) |
|
|
|
(5,948 |
) |
Balance at September 30, 2026 |
|
|
6,587,811 |
|
|
$ |
|
1 |
|
|
$ |
|
508,872 |
|
|
$ |
|
(440,639 |
) |
|
$ |
|
68,234 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Total |
|
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Stockholders' |
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity (Deficit) |
|
Balance at June 30, 2025 |
|
|
3,701,952 |
|
|
$ |
|
— |
|
|
$ |
|
419,931 |
|
|
$ |
|
(412,862 |
) |
|
$ |
|
7,069 |
|
Exercise of stock options |
|
|
78 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
Stock-based compensation expense |
|
|
— |
|
|
|
|
— |
|
|
|
|
1,123 |
|
|
|
|
— |
|
|
|
|
1,123 |
|
Net loss |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(16,287 |
) |
|
|
|
(16,287 |
) |
Balance at September 30, 2025 |
|
|
3,702,030 |
|
|
$ |
|
— |
|
|
$ |
|
421,054 |
|
|
$ |
|
(429,149 |
) |
|
$ |
|
(8,095 |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
XILIO THERAPEUTICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
For the nine months ended September 30, 2026 and 2025
(In thousands, except share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Total |
|
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Stockholders' |
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity |
|
Balance at December 31, 2025 |
|
|
4,530,641 |
|
|
$ |
|
— |
|
|
$ |
|
454,062 |
|
|
$ |
|
(418,789 |
) |
|
$ |
|
35,273 |
|
Issuance of prefunded warrants in connection with a follow-on offering, net of issuance costs |
|
|
— |
|
|
|
|
— |
|
|
|
|
37,256 |
|
|
|
|
— |
|
|
|
|
37,256 |
|
Issuance of common stock to settle the liabilities to issue common stock |
|
|
708,223 |
|
|
|
|
1 |
|
|
|
|
7,332 |
|
|
|
|
— |
|
|
|
|
7,333 |
|
Issuance of common stock in connection with the exercise of prefunded warrants |
|
|
743,410 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
Issuance of common stock in connection with at-the-market offerings, net of issuance costs |
|
|
592,300 |
|
|
|
|
— |
|
|
|
|
4,458 |
|
|
|
|
— |
|
|
|
|
4,458 |
|
Issuance of common stock under employee stock purchase plan |
|
|
4,973 |
|
|
|
|
— |
|
|
|
|
36 |
|
|
|
|
— |
|
|
|
|
36 |
|
Vesting of restricted stock units |
|
|
7,952 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
Exercise of stock options |
|
|
312 |
|
|
|
|
— |
|
|
|
|
1 |
|
|
|
|
— |
|
|
|
|
1 |
|
Stock-based compensation expense |
|
|
— |
|
|
|
|
— |
|
|
|
|
5,727 |
|
|
|
|
— |
|
|
|
|
5,727 |
|
Net loss |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(21,850 |
) |
|
|
|
(21,850 |
) |
Balance at September 30, 2026 |
|
|
6,587,811 |
|
|
$ |
|
1 |
|
|
$ |
|
508,872 |
|
|
$ |
|
(440,639 |
) |
|
$ |
|
68,234 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Total |
|
|
|
Common Stock |
|
|
Paid-In |
|
|
Accumulated |
|
|
Stockholders' |
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity (Deficit) |
|
Balance at December 31, 2024 |
|
|
3,268,299 |
|
|
$ |
|
— |
|
|
$ |
|
401,351 |
|
|
$ |
|
(383,753 |
) |
|
$ |
|
17,598 |
|
Issuance of prefunded warrants in connection with a follow-on public offering, net of issuance costs |
|
|
— |
|
|
|
|
— |
|
|
|
|
10,818 |
|
|
|
|
— |
|
|
|
|
10,818 |
|
Issuance of common stock in connection with the AbbVie stock purchase agreement, net of issuance costs |
|
|
310,559 |
|
|
|
|
— |
|
|
|
|
2,810 |
|
|
|
|
— |
|
|
|
|
2,810 |
|
Issuance of common stock in connection with at-the-market offerings, net of issuance costs |
|
|
110,747 |
|
|
|
|
— |
|
|
|
|
2,017 |
|
|
|
|
— |
|
|
|
|
2,017 |
|
Issuance of common stock under employee stock purchase plan |
|
|
3,240 |
|
|
|
|
— |
|
|
|
|
40 |
|
|
|
|
— |
|
|
|
|
40 |
|
Vesting of restricted stock units |
|
|
7,952 |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
Exercise of stock options |
|
|
1,233 |
|
|
|
|
— |
|
|
|
|
9 |
|
|
|
|
— |
|
|
|
|
9 |
|
Stock-based compensation expense |
|
|
— |
|
|
|
|
— |
|
|
|
|
4,009 |
|
|
|
|
— |
|
|
|
|
4,009 |
|
Net loss |
|
|
— |
|
|
|
|
— |
|
|
|
|
— |
|
|
|
|
(45,396 |
) |
|
|
|
(45,396 |
) |
Balance at September 30, 2025 |
|
|
3,702,030 |
|
|
$ |
|
— |
|
|
$ |
|
421,054 |
|
|
$ |
|
(429,149 |
) |
|
$ |
|
(8,095 |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
XILIO THERAPEUTICS, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
|
(21,850 |
) |
|
$ |
|
(45,396 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
996 |
|
|
|
|
1,218 |
|
Stock-based compensation expense |
|
|
|
5,727 |
|
|
|
|
4,009 |
|
Change in fair value of common stock warrant liabilities |
|
|
|
(4,180 |
) |
|
|
|
15,430 |
|
Issuance costs allocated to common stock warrant liabilities |
|
|
|
— |
|
|
|
|
2,284 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Collaboration and license agreement receivable |
|
|
|
5,000 |
|
|
|
|
(17,500 |
) |
Prepaid and other assets |
|
|
|
(1,283 |
) |
|
|
|
2,580 |
|
Accounts payable |
|
|
|
(1,973 |
) |
|
|
|
(276 |
) |
Accrued expenses and other liabilities |
|
|
|
(2,012 |
) |
|
|
|
(1,907 |
) |
Deferred revenue |
|
|
|
(35,324 |
) |
|
|
|
36,564 |
|
Net cash used in operating activities |
|
|
|
(54,899 |
) |
|
|
|
(2,994 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
(633 |
) |
|
|
|
(423 |
) |
Net cash used in investing activities |
|
|
|
(633 |
) |
|
|
|
(423 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from issuance of prefunded warrants in connection with a follow-on offering, net of issuance costs |
|
|
|
37,256 |
|
|
|
|
— |
|
Proceeds from issuance of common stock in connection with at-the-market offerings, net of issuance costs |
|
|
|
4,458 |
|
|
|
|
2,017 |
|
Proceeds from issuance of prefunded warrants and common stock warrants in connection with a follow-on offering, net of issuance costs |
|
|
|
— |
|
|
|
|
47,033 |
|
Proceeds from issuance of common stock in connection with the AbbVie stock purchase agreement, net of issuance costs |
|
|
|
— |
|
|
|
|
2,810 |
|
Proceeds from issuance of common stock under employee stock purchase plan |
|
|
|
36 |
|
|
|
|
40 |
|
Proceeds from exercise of stock options |
|
|
|
1 |
|
|
|
|
9 |
|
Payments of issuance costs included in accounts payable or accrued expenses at prior year end |
|
|
|
(1,550 |
) |
|
|
|
— |
|
Net cash provided by financing activities |
|
|
|
40,201 |
|
|
|
|
51,909 |
|
(Decrease) increase in cash, cash equivalents and restricted cash |
|
|
|
(15,331 |
) |
|
|
|
48,492 |
|
Cash, cash equivalents and restricted cash, beginning of period |
|
|
|
139,338 |
|
|
|
|
57,073 |
|
Cash, cash equivalents and restricted cash, end of period |
|
$ |
|
124,007 |
|
|
$ |
|
105,565 |
|
Supplemental disclosure of non-cash activities: |
|
|
|
|
|
|
|
|
Settlement of liabilities to issue common stock by issuing common stock |
|
$ |
|
7,332 |
|
|
$ |
|
— |
|
Reconciliation to amounts within the consolidated balance sheets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
|
122,182 |
|
|
$ |
|
103,764 |
|
Restricted cash |
|
|
|
1,825 |
|
|
|
|
1,801 |
|
Cash, cash equivalents and restricted cash, end of period |
|
$ |
|
124,007 |
|
|
$ |
|
105,565 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
XILIO THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements
(Dollars in thousands, unless otherwise stated)
(Unaudited)
1. Description of Business and Liquidity
Xilio Therapeutics, Inc. (“Xilio” or the “Company”) is a clinical-stage biotechnology company dedicated to discovering and developing masked immuno-oncology (“I-O”) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company was incorporated in Delaware in June 2020, and its headquarters are located in Waltham, Massachusetts.
Since its inception, the Company has devoted substantially all of its financial resources and efforts to research and development activities. As of September 30, 2026, the Company had an accumulated deficit of $440.6 million and has incurred significant operating losses, including net losses of $21.9 million and $45.4 million for the nine months ended September 30, 2026 and 2025, respectively. The Company expects its operating losses and negative operating cash flows to continue for the foreseeable future as it continues to advance its product candidates through clinical trials, maintains the infrastructure necessary to support these activities and continues to incur costs associated with operating as a public company.
As of September 30, 2026, the Company had cash and cash equivalents of $122.2 million. Based on its current operating plans, the Company anticipates that its existing cash and cash equivalents as of September 30, 2026 will be sufficient to enable it to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of the issuance of these condensed consolidated financial statements.
However, the Company has based its estimates on assumptions that may prove to be wrong. If actual results differ from the Company’s estimates, the Company could exhaust its available capital resources sooner than it anticipates, in which case, the Company would be required to seek additional capital sooner or curtail planned activities to reduce operating expenses, which may have an adverse impact on the Company’s ability to achieve its business objectives.
2. Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2025 and notes thereto, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2026. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the unaudited interim condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of September 30, 2026 and the results of its operations for the three and nine months ended September 30, 2026 and 2025 and cash flows for the nine months ended September 30, 2026 and 2025. Such adjustments are of a normal and recurring nature. The results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results for the year ending December 31, 2026 or for any future period.
On March 13, 2026, the Company effected a reverse stock split of its common stock at a ratio of 1-for-14. The reverse stock split did not impact the number of authorized shares of common stock or preferred stock or the par value per share of the common stock or preferred stock. All share and per share amounts in these condensed consolidated financial statements and notes thereto have been adjusted retroactively to reflect the reverse stock split for all periods presented.